Table 4. . Hemoglobin normalization efficacy odds ratios and transition probabilities for comparators.
| Efficacy odds ratios | |||
|---|---|---|---|
| Outcome | Probability | Odds ratio (comparator vs pegcetacoplan) | |
| Pegcetacoplan | Comparator | ||
| Eculizumab – normalization distribution: Normal | |||
| Hb normalized | 48.1% | 16.1% | 0.21 |
| Transfusion required | 7.8% | 33.9% | 6.09 |
| Eculizumab – normalization distribution: Weibull | |||
| Hb normalized | 48.1% | 21.3% | 0.29 |
| Transfusion required | 7.8% | 33.9% | 6.09 |
| Ravulizumab – normalization distribution: Normal | |||
| Hb normalized | 47.8% | 16.9% | 0.22 |
| Transfusion required | 5.6% | 26.4% | 5.99 |
| Ravulizumab – normalization distribution: Weibull | |||
| Hb normalized | 47.8% | 22.2% | 0.31 |
| Transfusion required | 5.6% | 26.4% | 5.99 |
| Transition probabilities | |||
| From | To | ||
| Hb normalized, % | Hb not normalized, % | Transfusion required, % | |
| Eculizumab – normalization distribution: Normal | |||
| Hb normalized | 18.0 | 70.0 | 12.0 |
| Hb not normalized | 16.9 | 55.6 | 27.5 |
| Transfusion required | 15.8 | 45.1 | 39.0 |
| Eculizumab – normalization distribution: Weibull | |||
| Hb normalized | 23.6 | 64.4 | 12.0 |
| Hb not normalized | 22.2 | 50.3 | 27.5 |
| Transfusion required | 20.9 | 40.0 | 39.0 |
| Ravulizumab – normalization distribution: Normal | |||
| Hb normalized | 5.1 | 69.1 | 11.9 |
| Hb not normalized | 17.9 | 54.9 | 27.2 |
| Transfusion required | 16.8 | 44.5 | 38.7 |
| Ravulizumab – normalization distribution: Weibull | |||
| Hb normalized | 24.8 | 63.3 | 11.8 |
| Hb not normalized | 23.4 | 49.4 | 27.2 |
| Transfusion required | 22.1 | 39.3 | 38.7 |
Hb: Hemoglobin.